Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025

Rhea-AI Summary

BioArctic (Nasdaq Stockholm: BIOA) announced on October 14, 2025 that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab for Alzheimer's disease, was selected by TIME as one of the Best Inventions of 2025 in the Medical and Healthcare category.

The selection recognizes the product's innovation and potential impact. Leqembi was developed in collaboration with Eisai, which leads clinical development, regulatory approvals and global commercialization. BioArctic retains rights to commercialize Leqembi in the Nordic region together with Eisai. Prescribing information in the US includes a Boxed WARNING.

STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease has been selected by TIME as one of the 'Best Inventions of 2025' in the Medical and Healthcare category.

TIME's annual list of the Best Inventions features 300 extraordinary innovations changing lives. To compile the 2025 list, TIME solicited nominations from TIME editors and correspondents around the world, and through an online application process, paying special attention to growing fields such as healthcare and AI. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact. For more information, please visit time.com/collections/best-inventions-2025/.

Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai is responsible for the clinical development, applications for market approval and commercialization of Leqembi for Alzheimer's disease. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialization in the region.

Please see full Prescribing Information for Leqembi in the US, including Boxed WARNING.

The information was released for public disclosure, through the agency of the contact person below, on October 14, 2025, at 07:00 a.m. CET.

For further information, please contact: 
Oskar Bosson, Vice President Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.com
Telephone: +46 70 410 71 80

About lecanemab (Leqembi^®)

Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

Lecanemab is approved in 50 countries including the U.S., Japan, China, and the European Union for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) and is under regulatory review in 10 countries. Leqembi Iqlik™ is approved for subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's disease in the US. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in China, the U.S. and others, and applications have been filed in 9 countries and regions.

Since July 2020, Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer's disease, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in Alzheimer's disease and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

About the collaboration between BioArctic and Eisai

Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization Agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody Leqembi back-up for Alzheimer's disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with regulatory approvals, and sales milestones as well as royalties on global sales.

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/bioarctic/r/leqembi--iqlik---lecanemab-irmb--selected-by-time-as-one-of-the-best-innovations-of-2025,c4249655

The following files are available for download:

https://mb.cision.com/Main/9978/4249655/3720329.pdf

Leqembi® Iqlikâ„¢ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025

 

View original content:https://www.prnewswire.com/news-releases/leqembi-iqlik-lecanemab-irmb-selected-by-time-as-one-of-the-best-innovations-of-2025-302582912.html

SOURCE BioArctic

FAQ

What did BioArctic announce about Leqembi Iqlik on October 14, 2025 (BIOA)?

BioArctic announced that Leqembi Iqlik was selected by TIME as one of the Best Inventions of 2025 in Medical and Healthcare.

What is Leqembi Iqlik and how is it administered (BIOA)?

Leqembi Iqlik is a subcutaneous autoinjector formulation of lecanemab intended for the treatment of Alzheimer's disease.

Who is responsible for Leqembi's clinical development and commercialization (BIOA)?

Eisai is responsible for clinical development, market approval applications and global commercialization; BioArctic and Eisai will jointly commercialize in the Nordic region.

Does Leqembi have safety cautions investors should note (BIOA)?

Yes; the US Prescribing Information for Leqembi includes a Boxed WARNING—investors should review official prescribing details.

Why did TIME select Leqembi Iqlik for Best Inventions of 2025?

TIME evaluated nominees on factors like originality, efficacy, ambition, and impact, and included Leqembi Iqlik in the Medical and Healthcare category.